PPARA and fatty liver disease: In this study, the injection of HFD-induced obese mice with MS-275 prevented hepatic steatosis by reducing de novo lipogenesis and increasing lipolysis and mitochondrial oxidation, by increasing the expression of oxidation-related genes, such as PPARα, MCAD, CPT1b, and FGF21.